SKIN CARE CLINIC BUSINESS PLAN

I. Executive Summary

Company Description

Aesthetic Science Clinic (name chosen to reflect a clinical, evidence-first approach) is a premier medical aesthetic clinic launching in 2026 in the U.S. medical aesthetics sector. We provide personalized, science-backed skin care through licensed practitioners using over $800,000 in FDA-cleared technology and diagnostic tools. Core offerings combine advanced in-clinic procedures and data-driven treatment plans with medical-grade retail to improve outcomes and increase lifetime value. One-line: evidence-first aesthetic care that pairs high-tech diagnostics with expert clinical delivery.

We deliver consultations, diagnostic imaging, minimally invasive procedures, corrective treatments, and curated medical-grade product sales in a modern, welcoming facility. What sets us apart is clinician-led protocols, objective outcome tracking, and integrated retail that reinforce clinical gains. We target adult consumers seeking measurable, medical-grade skin improvements and responsible anti-aging care. Short-term goal: open in 2026 and achieve operational stability. Long-term goal: standardize protocols, reach replicable unit economics, and expand to multiple locations. One-line: launch, stabilize, standardize, then scale.

Problem

Consumers face persistent skin problems—acne, visible aging, uneven tone—yet lack access to personalized, measurable, science-backed care. Over-the-counter products and traditional spas rarely provide diagnostics, baseline metrics, or treatment plans tied to individual skin biology.

Medical aesthetics demand is growing in the U.S., but current offerings leave a gap that a 2026 clinic with $800,000 in FDA-cleared technology, licensed practitioners, data-driven analysis, and medical-grade retail can fill. One-liner: patients need measurable, individualized treatment, not one-size-fits-all advice.

Solution

Expert-led, clinical skin health services delivered in a state-of-the-art medical clinic provide personalized, data-driven care for persistent acne, sun damage, aging, and body-shaping goals. Many consumers lack access to measurable, clinical treatment plans; our clinic pairs licensed clinicians with diagnostics to set, track, and adjust protocols so patients see objective progress and avoid wasted spend on ineffective over-the-counter options.

Services include comprehensive diagnostic consultations, laser therapy for skin rejuvenation, microneedling, chemical peels, body contouring, and personalized medical-grade at-home regimens—each treatment combines clinic procedures with tailored at-home care based on diagnostic baselines.

Mission Statement

We empower clients to achieve their healthiest, most radiant skin through personalized, science-backed care and objective, data-driven results. We combine clinical expertise and advanced technology in a professional, modern environment to deliver tangible aesthetic outcomes and long-term skin health. We commit to premium, client-centric care, high clinical standards, and treatments tailored to each client's unique biology.

Key Success Factors

Critical operational and financial drivers that must be met to achieve plan targets.

• 29-month payback on customer acquisition through high-margin services and tight cost control.
• Scale to 17 practitioners by 2030 to meet demand and preserve service levels.
• 6.98% ROE maintained via disciplined pricing, expense management, and capital allocation.
• Advanced diagnostic imaging to boost retention and justify premium pricing.
• Marketing CAC at 5.0% of revenue by Year 5 to sustain profitable growth.

Financial Summary

Financial snapshot for the Executive Summary: the clinic reaches breakeven in Feb 2026 and maintains a minimum cash balance of $191,000.

Financial requirements: initial capital covers specified CAPEX and operating runway; minimum cash forecast is $191,000 (Apr-26). Anticipated return: project IRR is 5.0% over the five-year forecast and ROE is 6.98%; payback occurs in 29 months.

Overall outlook: profitable early, growing EBITDA to $2.78M by 2030 and delivering modest investor returns.

Funding Requirements

We require $1,021,000 to buy equipment, complete the upscale clinic fit-out, stock products, and hold minimum cash through the April 2026 trough.

Breakeven is forecast for February 2026; EBITDA rises from $134,000 (year 1) to $2,783,000 by 2030, with a five-year IRR of 5.0% and a maintained minimum cash balance of $191,000.